Literature DB >> 11872761

Venous thromboembolic prophylaxis for transurethral prostatectomy: practice among British urologists.

A Golash1, P W Collins, H G Kynaston, B J Jenkins.   

Abstract

Venous thromboembolism (VTE) is an occasional cause of death after transurethral prostatectomy but there are no established guidelines for its prevention in relation to this operation. We assessed practice in the UK by mailing a questionnaire to 460 consultant members of the British Association of Urological Surgeons. 362 (79%) completed questionnaires were received. 280 of 362 (77%) respondents routinely used VTE prophylaxis with transurethral prostatectomy; 82 (23%) did not. 230 of the 280 urologists who took precautions used mechanical methods; 50 used low dose heparin, either with stockings or alone. This survey indicates that, despite a lack of clear evidence, most British urologists favour some form of precaution against VTE in patients undergoing transurethral prostatectomy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11872761      PMCID: PMC1279479          DOI: 10.1177/014107680209500305

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   18.000


  13 in total

1.  Incidence of venous thromboembolism verified by necropsy over 30 years.

Authors:  B Lindblad; N H Sternby; D Bergqvist
Journal:  BMJ       Date:  1991-03-23

2.  Prophylactic subcutaneous heparin does not increase operative blood loss in transurethral resection of the prostate.

Authors:  R G Wilson; D Smith; G Paton; J M Gollock; D N Bremner
Journal:  Br J Urol       Date:  1988-09

Review 3.  Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery.

Authors:  R Collins; A Scrimgeour; S Yusuf; R Peto
Journal:  N Engl J Med       Date:  1988-05-05       Impact factor: 91.245

4.  Role of extradural and of general anaesthesia in fibrinolysis and coagulation after total hip replacement.

Authors:  J Modig; T Borg; L Bagge; T Saldeen
Journal:  Br J Anaesth       Date:  1983-07       Impact factor: 9.166

5.  The effect of prophylactic subcutaneous heparin on blood loss during and after transurethral prostatectomy.

Authors:  M W Sleight
Journal:  Br J Urol       Date:  1982-04

6.  Thrombotic risk factors associated with transurethral prostatectomy.

Authors:  C R Bell; P J Murdock; K J Pasi; R J Morgan
Journal:  BJU Int       Date:  1999-06       Impact factor: 5.588

7.  Prevention of fatal postoperative pulmonary embolism by low doses of heparin. An international multicentre trial.

Authors: 
Journal:  Lancet       Date:  1975-07-12       Impact factor: 79.321

Review 8.  Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis.

Authors:  G P Clagett; J S Reisch
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

9.  A prospective study of the incidence of deep-vein thrombosis within a defined urban population.

Authors:  M Nordström; B Lindblad; D Bergqvist; T Kjellström
Journal:  J Intern Med       Date:  1992-08       Impact factor: 8.989

Review 10.  A comparison of general anesthesia and regional anesthesia as a risk factor for deep vein thrombosis following hip surgery: a critical review.

Authors:  M H Prins; J Hirsh
Journal:  Thromb Haemost       Date:  1990-12-28       Impact factor: 5.249

View more
  2 in total

1.  Transurethral resection versus holmium laser enucleation of the prostate: A prospective randomized trial comparing perioperative thrombin generation and fibrinolysis.

Authors:  Fuding Bai; Sheng Feng; Congcong Xu; Zhen Xu; Jijun Chen; Yichun Zheng
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

2.  Incidence and Risk Factors of Venous Thromboembolism in Patients After Transurethral Resection of the Prostate (TURP).

Authors:  Zhihuan Zheng; Ziqiang Wu; Kaixuan Li; Quan Zhu; Haozhen Li; Xuesong Liu; Guilin Wang; Zhengyan Tang; Zhao Wang
Journal:  Front Surg       Date:  2022-02-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.